113 related articles for article (PubMed ID: 16548918)
1. A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab.
Mittal S; Milner BJ; Johnston PW; Culligan DJ
Eur J Haematol; 2006 Jun; 76(6):531-4. PubMed ID: 16548918
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Williams KM; Higman MA; Chen AR; Schwartz CL; Wharam M; Colombani P; Arceci RJ
Pediatr Blood Cancer; 2008 Mar; 50(3):667-70. PubMed ID: 17318876
[TBL] [Abstract][Full Text] [Related]
3. T-cell gamma/delta hepatosplenic lymphoma - prolonged remission induced by aggressive first line treatment.
Procházka V; Papajík T; Jarosová M; Pikalová Z; Indrák K; Tichý M; Kucerová L; Fakan F; Bílý M; Starostka D
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):275-6. PubMed ID: 16601770
[TBL] [Abstract][Full Text] [Related]
4. Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation.
Kako S; Izutsu K; Oshima K; Sato H; Kanda Y; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2007 Oct; 82(10):937-9. PubMed ID: 17663389
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
[TBL] [Abstract][Full Text] [Related]
6. Successful allogeneic stem cell transplantation for Lennert lymphoma.
Uni M; Yoshimi A; Nakamura F; Takazawa Y; Fukayama M; Kurokawa M
Ann Hematol; 2013 Jun; 92(6):859-60. PubMed ID: 23224245
[No Abstract] [Full Text] [Related]
7. Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy.
Orlandi EM; Baldanti F; Citro A; Pochintesta L; Gatti M; Lazzarino M
Haematologica; 2008 Nov; 93(11):1758-60. PubMed ID: 18790800
[No Abstract] [Full Text] [Related]
8. Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma.
Bishton MJ; Haynes AP
Br J Haematol; 2007 Jan; 136(1):111-3. PubMed ID: 17116129
[TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
10. Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine.
Navarro JT; Ribera JM; Mate JL; Granada I; Juncà J; Batlle M; Millá F; Feliu E
Leuk Lymphoma; 2003 Mar; 44(3):531-3. PubMed ID: 12688327
[TBL] [Abstract][Full Text] [Related]
11. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma.
Zinzani PL; Alinari L; Tani M; Fina M; Pileri S; Baccarani M
Haematologica; 2005 May; 90(5):702-3. PubMed ID: 15921394
[TBL] [Abstract][Full Text] [Related]
12. Retinal hemorrhages as a presenting sign in an adolescent patient with hepatosplenic gamma-delta T-cell lymphoma.
Edwards J; Simmons E; Cordero S; Lieuw K; Roberts S
Pediatr Blood Cancer; 2010 Jul; 55(1):190-2. PubMed ID: 20486185
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma.
Weisel KC; Weidmann E; Anagnostopoulos I; Kanz L; Pezzutto A; Subklewe M
Int J Hematol; 2008 Nov; 88(4):434-440. PubMed ID: 18839273
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
Rzepecki P; Sarosiek T; Szczylik C
Jpn J Clin Oncol; 2006 Jan; 36(1):46-9. PubMed ID: 16423840
[TBL] [Abstract][Full Text] [Related]
15. Acute renal failure and disseminated intravascular coagulation following an idiosyncratic reaction to Alemtuzumab (Campath 1H) or fludarabine.
Osborne WL; Lennard AL
Haematologica; 2005 Jan; 90(1):ECR05. PubMed ID: 15653459
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis.
Cooles FA; Jackson GH; Menon G; Isaacs JD
Rheumatology (Oxford); 2011 Apr; 50(4):810-2. PubMed ID: 21208978
[No Abstract] [Full Text] [Related]
18. The role of alemtuzumab in the management of T-cell malignancies.
Dearden C
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S44-52. PubMed ID: 16720203
[TBL] [Abstract][Full Text] [Related]
19. Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation.
Avivi I; Chakrabarti S; Kottaridis P; Kyriaku C; Dogan A; Milligan DW; Linch D; Goldstone AH; Mackinnon S
Bone Marrow Transplant; 2004 Jul; 34(2):137-42. PubMed ID: 15235576
[TBL] [Abstract][Full Text] [Related]
20. EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.
Kluin-Nelemans HC; Coenen JL; Boers JE; van Imhoff GW; Rosati S
Blood; 2008 Aug; 112(4):1039-41. PubMed ID: 18502831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
